Rockwell Medical reports second quarter 2026 results and reiterates full-year guidance

Rockwell Medical, Inc. reported financial and operational results for the second quarter of 2026 on August 13, 2026, covering the three and six months ended June 30, 2026. Net sales for the three months ended June 30, 2026 were $17.8 million, an 11% increase over $16.1 million for the same period in 2025, which the company attributed to new business in the western United States and increased volume from current customers.¹

On the commercial side, the company disclosed two supply agreements finalized in May 2026. Rockwell Medical entered into a three-year product purchase agreement with Heritage Dialysis, with options for three additional one-year renewal periods.¹ Separately, it renewed and extended its existing purchase agreement with aQua Dialysis for a two-year term, with options for two additional one-year renewals.¹

The company also completed a corporate action affecting its share structure. In June 2026, Rockwell Medical announced a 1-for-10 reverse stock split intended to regain compliance with Nasdaq's $1.00 minimum bid price rule, effective July 1, 2026.¹ After the quarter closed, the company said Nasdaq notified it that compliance with Listing Rule 5550(a)(2) had been regained and the matter closed.¹

On cash and outlook, cash and cash equivalents and investments available-for-sale stood at $24.8 million as of June 30, 2026, up from $23.9 million at the end of the first quarter and roughly level with year-end 2025.¹ Rockwell Medical reiterated its 2026 annual guidance of net sales between $70.0 million and $75.0 million, gross margin of 18% to 22%, Adjusted EBITDA of $1.0 million to $2.0 million, and positive operating cash flow.¹